ArcherDX to Present at Cowen’s 2020 Liquid Biopsy Summit https://archerdx.com/archerdx-to-present-at-cowens-2020-liquid-biopsy-summit/

ArcherDX to Present at Cowen’s 2020 Liquid Biopsy Summit BOULDER, Colo., September 17, 2020 /PRNewswire/ – ArcherDX, Inc. today announced that Jason Myers, Ph.D., Chief Executive […]
ArcherDX to Participate in Morgan Stanley 18th Annual Global Healthcare Conference https://archerdx.com/archerdx-to-participate-in-morgan-stanley-18th-annual-global-healthcare-conference/

ArcherDX to Participate in Morgan Stanley 18th Annual Global Healthcare Conference BOULDER, Colo., September 8, 2020 /PRNewswire/ – ArcherDX, Inc. today announced that Jason Myers, Ph.D., […]
ArcherDX to Participate in UBS Genomics 2.0 and Medtech Innovations Virtual Summit https://archerdx.com/archerdx-to-participate-in-ubs-genomics-2-0-and-medtech-innovations-virtual-summit/

ArcherDX to Participate in UBS Genomics 2.0 and Medtech Innovations Virtual Summit BOULDER, Colo., August 5, 2020 /PRNewswire/ – ArcherDX, Inc. today announced that Jason Myers, […]
ArcherDX and UCL Extend TRACERx Program Collaboration to Evaluate Cancer Evolution https://archerdx.com/archerdx-and-ucl-extend-tracerx-program-collaboration-to-evaluate-cancer-evolution/

ArcherDX and UCL Extend TRACERx Program Collaboration to Evaluate Cancer Evolution — TRACERx program to utilize personalized, liquid biopsy-based research assays — BOULDER, Colo. and […]
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology https://archerdx.com/invitae-and-archerdx-to-create-a-global-leader-in-comprehensive-cancer-genetics-and-precision-oncology/

Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology — Combination to bring germline and somatic testing, liquid biopsy […]
ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research https://archerdx.com/archerdx-enters-collaboration-with-bristol-myers-squibb-to-apply-personalized-cancer-monitoring-pcm-to-clinical-research/

ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research Aims to Inform use of Minimal Residual Disease (MRD) […]
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD) https://archerdx.com/archerdx-announces-strategic-collaboration-with-astrazeneca-to-develop-personalized-cancer-monitoring-pcm-assays-for-minimal-residual-disease-mrd/

ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD) AstraZeneca to Leverage ArcherDX’s PCM Liquid Biopsy […]
ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions https://archerdx.com/archerdx-receives-breakthrough-device-designation-to-detect-ntrk-gene-fusions/

ArcherDX Receives Breakthrough Device Designation to Detect NTRK Gene Fusions BOULDER, Colo., May 19, 2020 /PRNewswire/ — ArcherDX, Inc. today announced that the U.S. Food […]
Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib) https://archerdx.com/bayer-and-archerdx-announce-global-collaboration-to-develop-next-generation-sequencing-ngs-based-companion-diagnostic-cdx-for-vitrakvi-larotrectinib/

Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib) Collaboration will focus on development of a companion […]
ArcherDX Appoints Jason Ryan to Board of Directors https://archerdx.com/archerdx-appoints-jason-ryan-to-board-of-directors/

ArcherDX Appoints Jason Ryan to Board of Directors BOULDER, Colo., May 7, 2020 /PRNewswire/ — ArcherDX, Inc. today announced the appointment of Jason Ryan, Chief […]